ÂÜÀòÂÒÂ×

Kapil Dhingra is an advisor at Tarveda Therapeutics. Kapil has also previously served as the chairman of the board at Exosome Diagnostics, a company which was acquired by Bio-Techne for up to $ 575 million. Dhingra has also been a member of the board of directors at Five Prime Therapeutics, Inc., a company which was acquired by Amgen for $ 1.9 billion.

Kapil Dhingra attended the All India Institute of Medical Sciences, where they earned their Doctor of Medicine (M.D.) degree in medicine.